BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35250995)

  • 1. Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies.
    Luo W; Napoleon JV; Zhang F; Lee YG; Wang B; Putt KS; Low PS
    Front Immunol; 2022; 13():816761. PubMed ID: 35250995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
    Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
    Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
    Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
    Front Immunol; 2020; 11():613215. PubMed ID: 33679700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
    Chen J; Zhu T; Jiang G; Zeng Q; Li Z; Huang X
    Mol Cancer; 2023 Aug; 22(1):131. PubMed ID: 37563723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target tumor microenvironment by innate T cells.
    Li YR; Wilson M; Yang L
    Front Immunol; 2022; 13():999549. PubMed ID: 36275727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor.
    Mathew AA; Zakkariya ZT; Ashokan A; Manohar M; Keechilat P; Nair SV; Koyakutty M
    Int Immunopharmacol; 2023 Jul; 120():110129. PubMed ID: 37201402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
    AntoƱana-Vildosola A; Zanetti SR; Palazon A
    Int Rev Cell Mol Biol; 2022; 370():123-147. PubMed ID: 35798503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
    Park JA; Wang L; Cheung NV
    J Hematol Oncol; 2021 Sep; 14(1):142. PubMed ID: 34496935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
    Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC; O'Connor RS; Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ
    Nat Commun; 2021 Feb; 12(1):877. PubMed ID: 33563975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
    Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
    Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
    Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy.
    Zhang B; Hu M; Ma Q; Li K; Li X; He X; Shu P; Chen Y; Gao G; Qin D; Guo F; Zhao J; Liu N; Zhou K; Feng M; Liao W; Li D; Wang X; Wang Y
    Mol Ther; 2023 Jul; 31(7):2105-2119. PubMed ID: 37073129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Targeted Delivery of an Immune Stimulant that Selectively Reactivates Exhausted CAR T Cells.
    Napoleon JV; Zhang B; Luo Q; Srinivasarao M; Low PS
    Angew Chem Int Ed Engl; 2022 Apr; 61(15):e202113341. PubMed ID: 35088497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors.
    Luo Q; Napoleon JV; Liu X; Zhang B; Zheng S; Low PS
    Mol Cancer Res; 2022 May; 20(5):823-833. PubMed ID: 35135862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
    Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
    Front Immunol; 2022; 13():867154. PubMed ID: 35603195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
    Fujimura T; Aiba S
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.